Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Hong J, Novick D, Montgomery W, Aguado J, Dueñas H, Peng X, Haro JM. Should unexplained painful physical symptoms be considered within the spectrum of depressive symptoms? Clin Pract Epidemiol Ment Health. 2015 Mar 31;11:130-9. doi: 10.2174/1745017901511010130
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Fleming A, Olson JA, Sharp PF, Goatman KA, Philip S. Response to 'Improved automated screening of diabetic retinopathy' by Carlos M. Oliveira et al. Ophthalmologica. 2012 Jan 1;227(3):173. doi: 10.1159/000334922